Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) EBIT (2021 - 2025)

Coeptis Therapeutics Holdings has reported EBIT over the past 5 years, most recently at -$2.0 million for Q4 2025.

  • Quarterly results put EBIT at -$2.0 million for Q4 2025, down 136.57% from a year ago — trailing twelve months through Dec 2025 was -$13.0 million (down 431.2% YoY), and the annual figure for FY2025 was -$13.0 million, down 431.2%.
  • EBIT for Q4 2025 was -$2.0 million at Coeptis Therapeutics Holdings, up from -$2.5 million in the prior quarter.
  • Over the last five years, EBIT for COEPW hit a ceiling of $42.8 million in Q4 2022 and a floor of -$15.7 million in Q1 2022.
  • Median EBIT over the past 5 years was -$2.9 million (2024), compared with a mean of -$1.1 million.
  • Peak annual rise in EBIT hit 413.59% in 2022, while the deepest fall reached 11004.82% in 2022.
  • Coeptis Therapeutics Holdings' EBIT stood at -$13.6 million in 2021, then surged by 413.59% to $42.8 million in 2022, then crashed by 67.83% to $13.8 million in 2023, then tumbled by 60.51% to $5.4 million in 2024, then tumbled by 136.57% to -$2.0 million in 2025.
  • The last three reported values for EBIT were -$2.0 million (Q4 2025), -$2.5 million (Q3 2025), and -$4.5 million (Q2 2025) per Business Quant data.